You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers from Kyoto University in Japan said the newly uncovered sequences may reflect ancient viruses and give insight into viral diversity.
Using a deep learning approach to study mutations in target sites of RNA-binding proteins, researchers identified DDHD2 as a candidate schizophrenia risk gene.
The Stanford University spinout cofounded by Euan Ashley will use the funding to develop its microfluidics-based cell sorting and analysis technology.
Tempus is developing a new predictive bioinformatics model to improve clinical trial enrollment for Janssen, while the pharma firm has joined Tempus' TIME Trial.
The new CompStor Insight combines hardware and software in one plug-and-play package and complements the vendor's Novos DNA assembly tool.
University spinout PercayAI will analyze genomic and clinical data from WUSTL's McDonnell Genome Institute in search of potential coronavirus drug combinations.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
The researchers also developed a web-based tool based on the data they gathered that could help predict COVID-19 severity in patients.
In a PrecisionFDA challenge, DeepVariant calls of PacBio HiFi reads topped 99 percent precision and recall for SNVs and indels, bringing HiFi in line with Illumina.
The integration on the Microsoft Azure cloud is helping Kaiser make its vast genomics dataset available to a wider pool of researchers.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.